- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03190772
The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation
November 6, 2018 updated by: Winfried Rief, Philipps University Marburg Medical Center
The study aimes at identifying whether positive expectations have an impact on the way depressive participants experience emotions in the form of sadness.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hessen
-
Gießen, Hessen, Germany, 35390
- Justus Liebig University Giessen
-
Marburg, Hessen, Germany, 35032
- Philipps University Marburg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- major depression (mild to moderate)
- fluent in German language
Exclusion Criteria:
- bipolar disorder, psychotic disorder, substance dependence
- cardiovascular disease, severe kidney or liver disease, epilepsy
- change of psychotropic medication intake within the last four weeks
- allergic to capsaicin
- allergic to sesame oil
- students in medicine, pharmacy, or psychology in their third year or older
- completed studies in medicine, pharmacy or psychology
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: No-treatment control group
Participants do not receive the nasal spray.
Participants watch a film sequence that is supposed to induce sadness.
|
All groups watch the film sequence that is supposed to induce sadness.
|
|
Experimental: Positive placebo group
Participants receive a placebo nasal spray.
However, they are told that it protects from experiencing negative emotions.
Participants watch a film sequence that is supposed to induce sadness.
|
The placebo nasal spray consists of sesame oil and does not contain any active drug.
All groups watch the film sequence that is supposed to induce sadness.
|
|
Placebo Comparator: Placebo control group
Participants receive a placebo nasal spray and are told that it is a placebo.
Participants watch a film sequence that is supposed to induce sadness.
|
The placebo nasal spray consists of sesame oil and does not contain any active drug.
All groups watch the film sequence that is supposed to induce sadness.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sadness
Time Frame: Directly after watching the film sequence, no follow-up assessments
|
Items of PANAS-X
|
Directly after watching the film sequence, no follow-up assessments
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Winfried Rief, Professor, Philipps University Marburg Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2017
Primary Completion (Actual)
September 30, 2018
Study Completion (Actual)
September 30, 2018
Study Registration Dates
First Submitted
June 14, 2017
First Submitted That Met QC Criteria
June 14, 2017
First Posted (Actual)
June 19, 2017
Study Record Updates
Last Update Posted (Actual)
November 7, 2018
Last Update Submitted That Met QC Criteria
November 6, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-12k
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Episode
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSignature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE) (SoLuRep)Major Depressive EpisodeFrance
-
University Hospital, MontpellierRecruitingMajor Depressive EpisodeFrance
-
Medical University of ViennaUnknownMajor Depressive EpisodeAustria
-
The University of New South WalesWesley MissionUnknown
-
Northside Clinic, AustraliaWesley MissionCompletedMajor Depressive EpisodeAustralia
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Jiangsu Province Nanjing Brain HospitalCompletedMajor Depressive EpisodeChina
-
Alto NeuroscienceRecruitingBipolar Disorder I or II With a Major Depressive EpisodeUnited States
-
Neumora Therapeutics, Inc.CompletedMajor Depressive Episode Associated With Bipolar II DisorderUnited States
-
Assistance Publique - Hôpitaux de ParisRecruiting
Clinical Trials on Placebo nasal spray
-
VistaGen Therapeutics, Inc.Recruiting
-
VistaGen Therapeutics, Inc.Active, not recruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
Alixer Nexgen Therapeutics LimitedRecruitingSeasonal Allergic Rhinitis (SAR)Canada
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Prime Gene Therapeutics Co., Ltd.Active, not recruiting
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Sichuan Purity Pharmaceutical Technology Co., Ltd.Recruiting
-
Chulalongkorn UniversityNot yet recruiting